为患有CMV结肠炎的UC患者优化类固醇治疗:一个多中心的现实研究
Haozheng Liang1, Linglin Tian2, Xiaowei Xue3
1Department of Gastroenterology, Peking Union Medical College, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, 100730, China.
性结肠炎 (UC) 患者的强化类固醇治疗改善了短期反应,并降低了与非启动相比的长期结肠切除风险. 这种策略不低于类固醇逐渐减少,强调个性化护理.
科学领域:
- 胃肠病学 胃肠病学
- 传染性疾病 传染性疾病
- 临床药理学 临床药理学
背景情况:
- 性结肠炎 (UC) 患者与同时发生的细胞巨化病毒 (CMV) 结肠炎经历了疾病严重程度的增加和更糟糕的预后.
- 抗病毒疗法是有益的,但最优的免疫抑制管理,特别是类固醇使用,仍然是有争议的.
研究的目的:
- 评估不同类固醇策略对住院UC患者同时患有CMV大肠炎的结果的影响.
- 为了比较胆管切除率和临床反应/缓解,基于CMV诊断后的类固醇管理.
主要方法:
- 一项回顾性两中心研究包括住院患者中度至重度UC和CMV结肠炎.
- 患者被分为三组:加强类固醇治疗,逐渐减少类固醇,或在CMV诊断后不启动类固醇.
- 多变量逻辑回归分析了26周和52周的切除风险,以及在第7天和第14天的临床反应/缓解,并调整了混因素.
主要成果:
- 与非启动组相比,强化类固醇组在26周 (调整OR=0.1) 和52周 (调整OR=0.1) 显示了显著较低的胆管切除风险.
- 在强化组 (调整后OR=4.5) 与非启动组中观察到更高的第7天临床响应率.
- 在强化和逐渐减少的类固醇组之间,没有发现短期或长期结果的显著差异.
结论:
- 对于CMV大肠炎的UC的类固醇策略需要根据先前的类固醇暴露进行个性化调整.
- 强化类固醇治疗优于不启动类固醇治疗,可以改善短期反应并降低长期切除风险.
- 在这些复杂的病例中,个性化治疗对于平衡即时和长期结果至关重要.
更多相关视频
05:41Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
Published on: April 6, 2022
07:45Ultrasound-guided Intracardiac Injection of Human Mesenchymal Stem Cells to Increase Homing to the Intestine for Use in Murine Models of Experimental Inflammatory Bowel Diseases
Published on: September 1, 2017
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
